COGT (Cogent Biosciences) Accumulated Depreciation: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

COGT Cogent Biosciences Inc COGT
30 GF Score
Price $37.89
! 3 Warning Signs
View Full Analysis

What is Cogent Biosciences Accumulated Depreciation?

Cogent Biosciences COGT -0.21% 30 Accumulated Depreciation is $0.00 Mil as of Jun. 2026. GuruFocus rates COGT with a GF Score™ of 30/100. The stock has 3 warning signs investors should review.

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Cogent Biosciences's quarterly accumulated depreciation declined from Dec. 2025 ($-8.68 Mil) to Mar. 2026 ($0.00 Mil) but then stayed the same from Mar. 2026 ($0.00 Mil) to Jun. 2026 ($0.00 Mil).

Cogent Biosciences's annual accumulated depreciation increased from Dec. 2023 ($-3.67 Mil) to Dec. 2024 ($-6.12 Mil) and increased from Dec. 2024 ($-6.12 Mil) to Dec. 2025 ($-8.68 Mil).

Cogent Biosciences Accumulated Depreciation Related Terms

Cogent Biosciences Accumulated Depreciation Historical Data

* Premium members only.

The historical data trend for Cogent Biosciences's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cogent Biosciences Accumulated Depreciation Chart

Cogent Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accumulated Depreciation
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.56 -1.40 -3.67 -6.12 -8.68

Cogent Biosciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -8.68 0.00 0.00
COGT
30GF Score
Cogent Biosciences Inc COGT
Accumulated Depreciation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cogent Biosciences Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

What does a Accumulated Depreciation of $0.00 Mil mean?
Cogent Biosciences (COGT) has a Accumulated Depreciation of $0.00 Mil as of Jun. 2026. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Cogent Biosciences and its competitors.
Is Cogent Biosciences' Accumulated Depreciation too high?
Cogent Biosciences' current Accumulated Depreciation is $0.00 Mil. Overall, Cogent Biosciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Cogent Biosciences' Accumulated Depreciation compare to MIRM and ERAS?
Cogent Biosciences' Accumulated Depreciation of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Biotechnology company?
A good Accumulated Depreciation depends on the Biotechnology industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Cogent Biosciences and its competitors. Cogent Biosciences's current Accumulated Depreciation is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cogent Biosciences stock overvalued right now?
Cogent Biosciences (COGT) has a current Accumulated Depreciation of $0.00 Mil. The current Accumulated Depreciation is $0.00 Mil. Cogent Biosciences' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For Cogent Biosciences (COGT), the current Accumulated Depreciation is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cogent Biosciences Business Description

Address 275 Wyman Street, 3rd Floor, Waltham, MA, USA, 02451
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
30GF Score

Get the complete analysis for COGT

Accumulated Depreciation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$37.89
Price